#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Czech Rheumatology / 2023 - 1

The role of Janus kinase inhibitors in the therapy of psoriatic arthritis

Czech version

Authors: H. Ciferská
Authors‘ workplace: Revmatologická klinika 1. LF UK, Praha ;  Revmatologický ústav Praha
Published in: Čes. Revmatol., 31, 2023, No. 1, p. 23-35.
Category: Reviews

Overview

 

Psoriatic arthritis (PsA) is a chronic autoimmune disease with manifestations involving the musculoskeletal apparatus (entheses, joints, axial skeleton),skin, and its adnexa (hair, nails), and other organ structures. PsA belongs to a heterogeneous group of spondyloarthritis and is thought to affect up to 30% of patients with psoriasis. PsA therapy includes non-pharmacological treatment, symptomatic treatment, conventional synthetic disease-modifying drugs, biological therapy with respective biosimilar variants (bsDMARDs), and targeted synthetic disease-modifying drugs (tsDMARDs), so-called small molecules. The newest group of drugs used in the treatment of PsA include tsDMARDs that inhibit selected Janus kinases.

Keywords:

Small molecules – Psoriatic arthritis – therapy – biologic therapy – JAK

Sources
  1. Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (London) 2017; 17(1): 65–70.
  2. Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet 2018; 391(10136): 2273–2284.
  3. Mease P, Goffe BS. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 2005; 52(1): 1–19.
  4. Taylor W, Gladman D, Helliwell P, et al. CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54(8): 2665–2673.
  5. Celis R, Planell N, Fernández-Sueiro JL, et al. Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Res Ther 2012; 27: R9.
  6. Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009; 228(1): 273–287.
  7. Maharaj AB, Chandran V. Treatment of psoriatic arthritis with traditional DMARD’s and novel therapies: approaches and recommendations. Expert Rev Clin Immunol 2016; 18 : 1–13.
  8. Coates LC, Soriano ER, Corp N, et al. GRAPPA Treatment Recommendations domain subcommittees. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 2022; 18(8): 465–479.
  9. Štolfa J. Biologická léčba psoriatické artritidy. Vnitř. Lék. 2018; 64(2): 127–135.
  10. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020; 79 : 700–712.
  11. Coates L, Gossec L. The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: Similarities and differences. Joint Bone Spine 2023; 90(1): 105469.
  12. Luo Y, Alexander M, Gadina M, et al. JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition. J Allergy Clin Immunol 2021; 148(4): 911–925.
  13. Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 2017; 16(12): 843–862.
  14. Gadina M, Le MT, Schwartz DM, et al. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology (Oxford) 2019; 58(Suppl 1): i4–i16.
  15. O’Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity 2008; 28 : 477–487.
  16. Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2016; 34 : 318–328.
  1. https://www.ema.europa.eu/en/documents/product-infor- mation/xeljanz-epar-product-information_cs.pdf [navštíveno 1. 11. 2022]
  2. Papp KA, Menter MA, Abe M, et al. OPT Pivotal 1 and OPT Pivotal 2 investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol 2015; 173(4): 949–961.
  3. Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib –⁠ an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2016; 34(2): 318–328.
  4. Mease P, Hall S, Fitzgerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 2017; 377 : 1537–1550.
  5. Nash P, Coates LC, Kivitz AJ, et al. Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study. Rheumatol Ther 2020; 7(3): 553–580.
  6. https://www.ema.europa.eu/en/documents/product-infor- mation/rinvoq-epar-product-information_cs.pdf  [navštíveno 1. 11. 2022]
  7. Campanaro F, Batticciotto A, Zaffaroni A, et al. JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis. Autoimmun Rev 2021; 20(10): 102902.
  8. Pavelka K. Targeted and biological drugs in the treatment of inflammatory rheumatic diseases. Vnitř. Lék. 2021; 67(4): 195–200.
  9. Serhal L, Edwards CJ. Upadacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2019; 15(1): 13–25.
  10. McInnes IB, Kato K, Magrey M, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open 2021; 7(3): e001838.
  11. McInnes IB, Anderson JK, Magrey M, et al. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N Engl J Med 2021; 384(13): 1227–1239.
  12. Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis 2021; 80(3): 312–320.
  13. Mease PJ, Lertratanakul A, Papp KA, et al. Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study. Rheumatol Ther 2021; 8(2): 903–919.
  14. https: //www.ema.europa.eu/en/documents/product-infor- mation/jyseleca-epar-product-information_cs.pdf [navštíveno 25. 10. 2022]
  15. White JPE, Coates LC. JAK1 selective inhibitors for the treatment of spondyloarthropathies. Rheumatology (Oxford) 2021; 60(Suppl 2): ii39–ii44.
  16. Gonzalez-Mazon I, Loricera J, Sanchez-Bilbao L, et al. AB0913 Efficiancy and safety of switching from filgotinib to tofacitinib in patients with psoriatic arthritis after 6 month of Follow up Annals of the Rheumatic Diseases 2022; 81 : 1586.
  17. Mease P, Coates LC, Helliwell PS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet 2018; 392(10162): 2367–2377.
  18. Orbai AM, Ogdie A, Gossec L, et al. Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR). Rheumatology (Oxford) 2020; 59(7): 1495–1504.
Labels
Dermatology & STDs Paediatric rheumatology Rheumatology
Editorial
Validation of the Czech Version of the Symptoms in Persons at Risk of Rheumatoid Arthritis (SPARRA) Questionnaire
Peripheral nervous system involvement in patients with systemic lupus erythematosus
Minutes of the meeting of the committee of the Czech Society for Rheumatology ČLS JEP (Třeboň, January 18, 2023)
Report from the ACR Convergence 2022 (Philadelphia, November 10–14, 2022)
POKYNY PRO AUTORY
Article was published in

Czech Rheumatology

Issue 1
2023 Issue 1
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#